ChromaDex
在场
ChromaDex 是一家在股票代码 CDXC (US) 下上市的公司。
高管
查看带有其 14 名主要高管的组织结构图
ChromaDex 搜索最多的简介
- Robert Fried, Chief Executive Officer and Director
- Kristin Patrick, Director
- Frank Jaksch, Executive Chairman of the Board
高管在ChromaDex变化
- Ozan Pamir已作为Chief Financial Officer加入公司 (新闻发布的2024九月23号).
- Carlos Lopez已作为Senior Vice President and General Counsel加入公司 (新闻发布的2024七月22号).
- James Lee 曾任 Controller, 现升职为 Interim Chief Financial Officer (新闻发布的2024七月19号).
创建提醒
跟踪 ChromaDex 的高管变动
药店
ChromaDex 拥有 1,842 家竞争者，其中包括 Pfizer (美国(美洲))、Johnson & Johnson (美国(美洲)) 和 Sanofi (法国)。
Popular M&A news in 药店
- Stemtech and Seacret Direct have announced they will merge (公布2024十一月22号)..
- BeiGene将改名为BeOne Medicines。 (公布2024十一月15号).
- GlycoMimetics and Crescent Biopharma have announced they will merge (公布2024十一月15号)..
药店 行业的其他推荐联系人
消息
ChromaDex 的最新新闻稿
- ChromaDex’s Patented Nicotinamide Riboside (NR) Ingredient, Niagen®, Featured as the Hero Ingredient in Longevity.Technology’s Inaugural Longevity Supplement
- ChromaDex's Pharmaceutical-Grade Niagen® IV Now Accessible at over 200 Restore Hyper Wellness Clinics Nationwide
- ChromaDex Corporation Reports Third Quarter 2024 Financial Results
- ChromaDex Corporation Reports Third Quarter 2024 Financial Results
- ChromaDex to Report Third Quarter 2024 Financial Results on Thursday, October 31, 2024
- ChromaDex to Participate in the 17th Annual LD Micro Main Event
- ChromaDex to Report Third Quarter 2024 Financial Results on Thursday, October 31, 2024
- Niagen+ | Pharmaceutical-grade Niagen (NR) IV and Injectable
- Yasmeen Nkrumah-Elie, Ph.D., Global Director of External Research at ChromaDex, Honored with the Trailblazing Woman Award by Radicle Science and Council for Responsible Nutrition (CRN)
- ChromaDex to Participate in a Fireside Chat at the Lytham Partners Fall 2024 Investor Conference
- View more press releases Close
关于 ChromaDex 的社交媒体
保持联系
通过电子邮件联系联系该企业高管，包括 Frank Jaksch 
